Goldman Sachs initiated coverage on Quotient with a new price target
$QTNT
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Goldman Sachs initiated coverage of Quotient with a rating of Neutral and set a new price target of $5.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/3/2021 | $4.00 → $3.50 | Neutral | Goldman Sachs |
| 8/6/2021 | $5.00 → $4.50 | Neutral | Goldman Sachs |